Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Barbara Koetz"'
1
A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE)
Autor: Ecaterina Ileana Dumbrava, Ravi Murthy, Barbara Koetz, Andrew Fox, Hilary McElwaine-Johnn, Aung Naing, Paul Cockle, Funda Meric-Bernstam, David Krige, Jo Carter, Brian Robert Champion
Publikováno v: Journal of Clinical Oncology. 37:TPS2668-TPS2668
TPS2668 Background: NG-350A is a transgene modified variant of the oncolytic platform virus enadenotucirev (EnAd) which expresses a fully human agonist anti-cluster of differentiation 40 (anti-CD40) antibody. The principal advantage of encoding anti-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82790f186d31ef8d98a1f1fc9196c3b4
https://doi.org/10.1200/jco.2019.37.15_suppl.tps2668
Zobrazit plný text záznamu
2
Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors
Autor: Marja Mergui-Roelvink, Margarita Lymboura, Arturo Lopez-Anaya, A. C. Dubbelman, Jan H.M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen, Larisa Reyderman, Barbara Koetz, Hilde Rosing, Robert S. Jansen
Publikováno v: Drug Metabolism and Disposition. 40:313-321
This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single approximately 2 mg (approximately 80 μCi) do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bedbbd792136d13055ff2e96b1d6d49e
https://doi.org/10.1124/dmd.111.042762
Zobrazit plný text záznamu
4
Positron Emission Tomography
Autor: Patricia M Price, Barbara Koetz
Publikováno v: Radiotracers in Drug Development ISBN: 9780849333477
Radiotracers in Drug Development
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7b9d5e1bb46034de9e4d4b8c6284c62
https://doi.org/10.1201/9780849333477.ch11
Zobrazit plný text záznamu
5
Abstract 1294: Metabolism and excretion of eribulin in patients with advanced solid tumors
Autor: Arturo Lopez-Anaya, Hilde Rosing, Margarita Lymboura, Marja Mergui-Roelvink, Barbara Koetz, Larisa Reyderman, Serena Marchetti, Jan H.M. Schellens, Jos H. Beijnen, A. C. Dubbelman
Publikováno v: Cancer Research. 71:1294-1294
This Phase I, open-label, mass-balance study investigated the metabolism and excretion of eribulin, a non-taxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single 14C-eribulin acetate (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::661451614314cfecea01fd92cdcfb799
https://doi.org/10.1158/1538-7445.am2011-1294
Zobrazit plný text záznamu
6
Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
Autor: Azeem Saleem, Anwar R. Padhani, Barbara Koetz, J. James Stirling, G. J. S. Rustin, Patricia M Price, D. M. Patterson, Mike Stratford, Paul Ross, Marie-Claude Asselin
Publikováno v: Journal of Clinical Oncology. 25:14146-14146
14146 Background: OXi4500, the active product of OXi4503, is a vascular disrupting agent acting at the colchicine binding site on the β subunit of tubulin. OXi4503 has greater anti-tumour activity in human cancer cell lines, causes a greater reducti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33eb8c9aad7a1dcb7a65519ef926ffde
https://doi.org/10.1200/jco.2007.25.18_suppl.14146
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje